tositumomab
Sign in to saveAlso known as Ig gamma-1 chain C region, Bexxar
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody.
Research
361 papers- Tositumomab I 131.2006
- Tositumomab.2012
- I-131 tositumomab.Expert opinion on biological therapy · 2010
- Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2005
- (131)I-Tositumomab.2004
via PubMed
~3 min read
Encyclopedic overview
5 sectionsContents
- Clinical use
- Availability
- United States
- Europe
- References
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody.
The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in 2005. It was sold for about $25,000 for one round of treatment. Bexxar competed with Zevalin, until the former's discontinuation in 2014.
Excerpted from Wikipedia’s “tositumomab” article, available under the CC BY-SA 4.0 licence.
Available in 6 languages
via Wikidata sitelinks · CC0